Advances in the management of differentiated thyroid cancer with follicular cell strain

##plugins.themes.academic_pro.article.sidebar##

Published Aug 15, 2016
Download
pdf
Vol. 94 No. 3 (2016): Issue Mar 2016

##plugins.themes.academic_pro.article.main##

Faouzi Ben Slimène
Aida Mhiri
Moez Ben Ali
Hédia Slimène
Nouzha Ben Raies
Esma Karboua
Martin Schlumberger

Abstract

The management of nodules and thyroid cancer is evolving. The aim is to individualize the treatment, decreasing aggression in the forms low risk and instead seeking new therapeutic options in advanced disease. This update shows the main recent advances in this field.

Keywords:

Differentiated Thyroid Cancer - Follicular - Management

##plugins.themes.academic_pro.article.details##

References

  1. Cooper DS, Doherty GM, Haugen BR, et al. The American Thyroid Association Guidelines Task Force. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
  2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States 2006; 295: 2164-2167.
  3. Russ G, Royer B, Bigorgne C, Rouxel A, Bienvenu-Perrard M, Leenhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol 2013; 168: 649-55.
  4. Baloch ZW, Livolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:425-37
  5. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20:1341-9.
  6. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.Thyroid 2013; 23:1401-7
  7. Mallick U, Harmer C, Yap B, Wadsley J, et al. Ablation with low-dose radioiodine and thyrotropinalfain thyroid cancer. N Engl J Med 2012; 366:1674-85.
  8. Schlumberger M, Catargi B, Borget I, et al. Tumeurs de la thyroïde refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in low-risk thyroid cancer patients. N Engl J Med 2012; 366: 1663-73.
  9. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011; 96: 1352-9.
  10. Gemsenjager E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003 ; 197: 182-190.
  11. Gimm, O, Rath FN, Dralle H. Pattern of lymphnodemetastases in papillary thyroid carcinoma. Br J Surg 1998; 85: 252-254.
  12. Goshen E, Cohen O, Rotenberg G et al. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003; 24: 959-61.
  13. Xing MM, Haugen B, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058-69.
  14. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348-54
  15. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F Definition and management of radioactive iodine-refractory differentiated thyroid cancer: Recommendations by an International Expert Panel. Lancet Diabetes & Endocrinol 2014; 2: 356-8.
  16. Schlumberger M. Prise en charge des cancers réfractaires de la thyroïde. Annales d'endocrinologie 2011; 72 (2) : 149-157.
  17. Schlumberger M, Elisei R, Elisei R, et al. For the motesanib thyroid cancer study group. Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27: 3794-3801.
  18. Hoftijzer H, Heemstra K, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161: 923-931.
  19. Bible KC, Suman VJ, Molina JR et al. Endocrine malignancies disease oriented group; mayo clinic cancer center; mayo phase 2 consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010 ; 11 : 962-972.
  20. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive, differentiated thyroid cancer N Engl J Med 2008; 359: 31-42.